CA3245205A1 - METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT - Google Patents

METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT

Info

Publication number
CA3245205A1
CA3245205A1 CA3245205A CA3245205A CA3245205A1 CA 3245205 A1 CA3245205 A1 CA 3245205A1 CA 3245205 A CA3245205 A CA 3245205A CA 3245205 A CA3245205 A CA 3245205A CA 3245205 A1 CA3245205 A1 CA 3245205A1
Authority
CA
Canada
Prior art keywords
insert
day
eye
days
vorolanib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3245205A
Other languages
English (en)
French (fr)
Inventor
Said Saim
Jay S. DUKER
Dario PAGGIARINO
Michelle Howard-Sparks
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of CA3245205A1 publication Critical patent/CA3245205A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3245205A 2022-03-11 2023-03-10 METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT Pending CA3245205A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263318822P 2022-03-11 2022-03-11
US63/318,822 2022-03-11
US202263390036P 2022-07-18 2022-07-18
US63/390,036 2022-07-18
PCT/US2023/064139 WO2023173088A1 (en) 2022-03-11 2023-03-10 Method of preventing age-related macular degeneration by administering an ocular drug delivery insert

Publications (1)

Publication Number Publication Date
CA3245205A1 true CA3245205A1 (en) 2023-09-14

Family

ID=85873993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3245205A Pending CA3245205A1 (en) 2022-03-11 2023-03-10 METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT

Country Status (9)

Country Link
US (1) US20250205152A1 (enExample)
EP (1) EP4489749A1 (enExample)
JP (1) JP2025508127A (enExample)
KR (1) KR20250002220A (enExample)
AU (1) AU2023230975A1 (enExample)
CA (1) CA3245205A1 (enExample)
IL (1) IL315331A (enExample)
TW (1) TW202345803A (enExample)
WO (1) WO2023173088A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
CA3066437A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda

Also Published As

Publication number Publication date
TW202345803A (zh) 2023-12-01
IL315331A (en) 2024-10-01
KR20250002220A (ko) 2025-01-07
EP4489749A1 (en) 2025-01-15
US20250205152A1 (en) 2025-06-26
WO2023173088A1 (en) 2023-09-14
AU2023230975A1 (en) 2024-09-19
JP2025508127A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
US12551368B2 (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250205152A1 (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
US20230089914A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
US20250186336A1 (en) Method of treating wet age-related macular degeneration
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
HK40118703A (en) Method of treating wet age-related macular degeneration
HK40118700A (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118701A (en) Continuous dosing regimen for treatment of a condition of the eye
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
US20250025452A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240829

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240903

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240903

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250804